The evolution of research and development in the pharmaceutical industry: Toward the open innovation model - Can pharma reinvent itself?

International Journal of Business Innovation and Research

Volumn 5, Issue 1, 2011, Pages 63-74

  Subramanian, Ram ^a   Toney, Jeffrey H ^b   Jayachandran, C ^a  

^a MONTCLAIR STATE UNIVERSITY   (United States)

^b KEAN UNIVERSITY   (United States)

Author keywords

Open innovation; Pharmaceutical industry; R D; Research and development

Indexed keywords

EID: 78649802381     PISSN: 17510252     EISSN: 17510260     Source Type: Journal    
DOI: 10.1504/IJBIR.2011.037257     Document Type: Article

References (26)

1. Barnett, W.P. and Hansen, M.T. (1996) 'The Red Queen in organizational evolution', Strategic Management Journal, Vol. 17, pp.139-157.
2. Bresciani, S. (2009) 'Innovation and creativity within firms; an empirical demonstration in the Piedmont area', International Journal of Business Innovation and Research, Vol. 3, No. 4, pp.427-443.
3. Chesbrough, H. (2006) Open Business Models: How to Thrive in the New Innovation Landscape, Harvard Business School Press, Boston.
4. Chesbrough, H. (2007) 'Why companies should have open business models', MIT Sloan Management Review, Vol. 48, No. 2, pp.22-28.
5. Chesbrough, H. and Schwartz, K. (2007) 'Innovating business models with co-development partnerships', Research Technology Management, Vol. 50, No. 1, pp.55-59.
6. Chesbrough, H., Vanhaverbeke, W. and West, J. (2006) Open Innovation: Researching a New Paradigm, Oxford University Press, London.
7. Christensen, C.M. (1997) Innovator's Dilemma: When New Technologies Cause Great Firms to Fail, Harvard Business School Press, Boston.
8. Czuchry, A.J., Yasin, M.M. and Peisi, T.M. (2009) 'A systematic approach to promoting effective innovation: a conceptual framework and managerial implications', International Journal of Business Innovation and Research, Vol. 3, No. 6, pp.575-595.
9. Elmquist, M., Fredberg, T. and Ollila, S. (2009) 'Exploring the field of open innovation', European Journal of Innovation Management, Vol. 12, No. 3, pp.326-345.
10. Engardio, P. and Weintraub, A. (2008) 'Outsourcing the drug industry', Business Week, 15 September, pp.49-53.
11. Freeman, J. and Engel, J.S. (2007) 'Models of innovation: startups and mature corporations', California Management Review, Vol. 50, No. 1, pp.94-119.
12. Garnier, J. (2008) 'Rebuilding the R&D engine in big pharma', Harvard Business Review, Vol. 86, No. 12, pp.68-76.
13. Jack, A. (2009) 'An acute talent for innovation', Financial Times, 2 February, p.10.
14. Loewe, P. and Chen, G. (2007) 'Changing your company's approach to innovation', Strategy & Leadership, Vol. 35, No. 6, pp.18-26.
15. Longman, R. (2009) 'Windhover's pharmaceutical strategic outlook', available at www.windhover.com/pso.
16. Nambisan, S. and Sawhney, M. (2007) 'A buyer's guide to the innovation bazaar', Harvard Business Review, Vol. 85, No. 6, pp.109-118.
17. Novak, S. and Stern, S. (2009) 'Complementarity among vertical integration decisions: evidence from automobile product development', Management Science, Vol. 55, No. 2, pp.311-333.
18. Ortt, J.R. and van der Duin, P.A. (2008) 'The evolution of innovation management towards contextual innovation', European Journal of Innovation Management, Vol. 11, No. 4, pp.522-538.
19. Pharmaceutical Researchers and Manufacturers of America (PhRMA) (2008) Annual Report 2008.
20. Rhyne, I.C. (2009) 'Business model design for biotechnology firms', International Journal of Business Innovation and Research, Vol. 3, No. 3, pp.298-310.
21. Salmi, P. and Torkkei, M. (2009) 'Success factors of interorganizational knowledge transfer: a case of a collaborative public-private R&D project', International Journal of Business Innovation and Research, Vol. 3, No. 2, pp.109-125.
22. Standard & Poor's Industry Surveys (S&P) (2008) Healthcare: Pharmaceuticals.
23. Tidd, J. (2006) A Review of Innovation Models, Tanaka Business School Report, Imperial College London.
24. Tijssen, R.J.W. (2009) 'Internationalisation of pharmaceutical R&D: how globalized are Europe's largest multinational companies', Technology Analysis and Strategic Management, Vol. 21, No. 7, pp.859-871.
25. Vernon, J.A., Golec, J.H., Lutter, R. and Nardinelli, C. (2009) 'An exploratory study of FDA new drug review times, prescription drug user free acts, and R&D spending', Quarterly Review of Economics and Finance, Vol. 49, No. 4, pp.1260-1281.
26. Wang, J. and Kleiner, B.H. (2005) 'The evolution of R&D management', Management Research News, Vols. 11/12, pp.88-95.